Small Business: Anti-Infective Therapeutics – DCAI (12)

Topics

• Development and/or testing of novel anti-infective small molecule agents or therapeutic to fight infective agents using culture systems or animal models
• Development of processes to optimize industrial production of anti-infective (small molecule) agents

Shared Interests and Overlaps:

There are shared interests with Anti-infective therapeutics, diagnostic immunology, and decontamination [DCAI (14)] in the development and/or testing of novel anti-infective agents or therapeutics. Small business applications focused on the development of large molecule therapeutics (e.g. peptides, antibodies), or therapeutics directly targeting the immune responses against microorganisms, will be reviewed at DCAI 14. Small business applications focused on the development of small molecule therapeutics targeting the pathogen will be reviewed here.

There are shared interests with Microbial Diagnostics and Detection [DCAI (13)] in the advancement of anti-infective approaches. Small business applications addressing the development of agents or methods to detect or combat biofilms in vivo and on medical devices may be reviewed in DCAI (13), whereas applications that seek to develop antibiotic agents that include effectiveness in the context of biofilms may be reviewed here.

There are shared interests with Biological Chemistry, Biophysics, and Assay Development [MCST (10)] in the area of assay development. Small business applications addressing fundamental assay development or disease-agnostic assays may be reviewed in MCST (10). Applications focused on the microbiology may be reviewed here.

There are shared interests with Drug Discovery and Development [MBBC (10)] in the advancement of anti-infective approaches. Small business applications that address the development of synthetic small molecules and natural products or address large-scale synthesis for the manufacture of antimicrobial drugs, or seek to advance computational approaches to the discovery of antimicrobial agents, or advance assay development and screening techniques to support antimicrobial development may be reviewed in MBBC (10). Applications that screen small molecule libraries for anti-infective activity may be reviewed here.

There are shared interests with Computational, Modeling, and Biodata Management [MCST (14)] in the advancement of anti-infective approaches. Small business applications that address computational modeling, image processing and systems biology approaches for antimicrobial drug development may be reviewed in MCST (14) if the focus is on the development of the technology. Applications that focus on the utilization of the technology for drug development may be reviewed here.